Skip to main content
Delfa

← All assets

Cannabidiol

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

4

Recruiting

3

Completed

0

Sites

9

Countries

4

Endpoints

45

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 45 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
3
Phase 2/3
1
Phase 4
1

Trials by status

Not yet recruiting
1
Recruiting
3
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
14
Global cognition
9
Memory
6
Other (unclassified)
6
Caregiver / quality of life
4
Fluid / digital biomarkers
3
Executive function / language
1
Disease progression
1
Neurodegeneration biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 11 of 45 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

3

Mini-Mental State Examination (MMSE)Cognition

3

Montreal Cognitive Assessment (MoCA)Cognition

2

ADAS-CogCognition

2

Phosphorylated tau 181 (p-tau181)Progression

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
CALM-ITCannabidiol Medication Intervention Trial

Cannabidiol

Alzheimer’s disease

Alzheimer's diseasePh 2Recruiting5Dec 2026-
NCT05822362CBD for Individuals at Risk for Alzheimer's Disease

Cannabidiol

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MoCA ≤25Ph 2Recruiting1Apr 2028-
NCT05022186The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Cannabidiol, Homotaurine

MCI / preclinical Alzheimer’s

Age 65-85Ph 4Unknown1Dec 2022-
NCT04436081Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

Cannabidiol

Alzheimer’s disease

Alzheimer's diseasePh 2Recruiting1Mar 202413
MyC4DCannabidiol's Role in Dementia Management

Cannabidiol

Mixed / unspecified dementia

Age ≥50Ph 2/3Not yet recruiting1Oct 2025-

Showing 1-5 of 5 trials